Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?

被引：13
|
作者：
Ferrara, Felicetto [1 ]
机构：
[1] Cardarelli Hosp, Div Hematol, Naples, Italy
来源：
BLOOD CANCER JOURNAL | 2020年 / 10卷 / 01期
关键词：
UPDATE;
D O I：
10.1038/s41408-020-0281-x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients
    Faderl, Stefan
    Ravandi, Farhad
    Huang, Xuelin
    Wang, Xuemei
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Kadia, Tapan
    Ferrajoli, Alessandra
    Konopleva, Marina
    Borthakur, Gautam
    Burger, Jan
    Feliu, Jennie
    Kantarjian, Hagop M.
    CANCER, 2012, 118 (18) : 4471 - 4477
  • [22] LOW-DOSE CYTARABINE IN THE TREATMENT OF ACUTE MYELOID-LEUKEMIA
    BERIS, P
    RIEDER, A
    ANDREY, C
    HELG, C
    CHAPUIS, B
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1984, 114 (48) : 1763 - 1766
  • [23] Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia
    Wei, Andrew
    Strickland, Stephen A.
    Roboz, Gail J.
    Hou, Jing-Zhou
    Fiedler, Walter
    Lin, Tara L.
    Martinelli, Giovanni
    Walter, Roland B.
    Enjeti, Anoop
    Fakouhi, Kaffa
    Darden, David E.
    Dunbar, Martin
    Zhu, Ming
    Agarwal, Suresh
    Salem, Ahmed H.
    Mabry, Mack
    Hayslip, John
    BLOOD, 2016, 128 (22)
  • [24] Venetoclax in Combination With Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia: Clinical Experience From a Real-Life Setting
    Piccini, Matteo
    Gianfaldoni, Giacomo
    Mannelli, Francesco
    Scappini, Barbara
    Ciolli, Gaia
    Pasquini, Andrea
    Fasano, Laura
    Pilerci, Sofia
    Quinti, Elisa
    Crupi, Francesca
    Guglielmelli, Paola
    Vannucchi, Alessandro Maria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S285 - S286
  • [25] Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy
    Yamauchi, Takahiro
    Yoshida, Chikashi
    Usuki, Kensuke
    Takada, Satoru
    Matsumura, Itaru
    Dobashi, Nobuaki
    Miyazaki, Yasushi
    Miyamoto, Toshihiro
    Iida, Hiroatsu
    Asou, Norio
    Kuroda, Junya
    Ichikawa, Satoshi
    Komatsu, Norio
    Mendes, Wellington
    Honda, Hideyuki
    Okubo, Sumiko
    Kurokawa, Misaki
    Jiang, Qi
    Wei, Andrew
    Ishizawa, Kenichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (09) : 1372 - 1382
  • [26] The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement
    Otoukesh, Salman
    Zhang, Jianying
    Nakamura, Ryotaro
    Stein, Anthony S.
    Forman, Stephen J.
    Marcucci, Guido
    Pullarkat, Vinod
    Aldoss, Ibrahim
    LEUKEMIA & LYMPHOMA, 2020, 61 (08) : 2020 - 2023
  • [27] Efficacy of hypomethylating agents and Venetoclax in unfit patients with acute myeloid leukemia
    Rieger, M.
    Manz, M. G.
    Muller, R.
    Theocharides, A. P. A.
    Schwotzer, R.
    SWISS MEDICAL WEEKLY, 2020, : 17S - 17S
  • [28] Venetoclax Combined with Either a Hypomethylating Agent or Low-Dose Cytarabine Shows Activity in Relapsed and Refractory Myeloid Malignancies
    Goldberg, Aaron D.
    Horvat, Troy Z.
    Hsu, Meier
    Devlin, Sean M.
    Cuello, Bernadette M.
    Daley, Ryan J.
    King, Amber C.
    Buie, Larry W.
    Glass, Jacob L.
    Mauro, Michael J.
    Stein, Eytan M.
    Berman, Ellin
    Klimek, Virginia M.
    Tallman, Martin S.
    BLOOD, 2017, 130
  • [29] Clinical Outcomes and Cardiovascular Adverse Events of Patients with Acute Myeloid Leukemia Treated with Venetoclax Plus a Hypomethylating Agent or Low-Dose Cytarabine in the Veterans Health Administration: A National Retrospective Cohort Study
    Souza, Gabriel Roman
    Lucero, Kana Tai
    Mines, Ian
    Latiolais, Heidi
    Franklin, Kathleen
    Mader, Michael
    Nooruddin, Zohra
    BLOOD, 2023, 142
  • [30] Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan
    Asada, Noboru
    Ando, Jun
    Takada, Satoru
    Yoshida, Chikashi
    Usuki, Kensuke
    Shinagawa, Atsushi
    Ishizawa, Kenichi
    Miyamoto, Toshihiro
    Iida, Hiroatsu
    Dobashi, Nobuaki
    Okubo, Sumiko
    Honda, Hideyuki
    Soshin, Tomomi
    Nishimura, Yasuko
    Tsutsui, Atsuko
    Mukai, Harumi
    Yamamoto, Kazuhito
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (07) : 595 - 603
12345